ADC / XDC

Delve into the world of ADC / XDC in China’s pharmaceutical industry. Fineline Info & Tech provides reliable data, news, and insights on ADC / XDC to help you navigate complexities with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Company Drug

Huadong Medicine’s Oral GLP‑1 Agonist Conveglipron Trometamol (HDM1002) Clears NMPA Marketing Application Acceptance for Long‑Term Weight Control in Adults

Huadong Medicine Co., Ltd. (SHE: 000963) announced that the marketing application for Conveglipron Trometamol Tablets (development code: HDM1002 tablets) for long‑term weight control in adults has been accepted by China's…

November 6, 2026

Pfizer’s Hympavzi Wins NMPA Approval for a New Indication in China – World’s First Once‑Weekly Non‑Factor Subcutaneous Therapy Extends to Hemophilia A and B with Inhibitors

November 6, 2026

Hybio Pharmaceutical’s Oral HY3003 Tablets Clear NMPA Clinical Trial Application Acceptance – A Class 1 GLP‑1R/GIPR/GCGR Triple Agonist for Weight Loss, Type 2 Diabetes, and MASH

November 6, 2026

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.

Explore Now

OBI Pharma Partners with TegMine to Develop Antibody-Drug Conjugates

Company Deals

ADC / XDC

Huadong Medicine’s Oral GLP‑1 Agonist Conveglipron Trometamol (HDM1002) Clears NMPA Marketing Application Acceptance for Long‑Term Weight Control in Adults

Pfizer’s Hympavzi Wins NMPA Approval for a New Indication in China – World’s First Once‑Weekly Non‑Factor Subcutaneous Therapy Extends to Hemophilia A and B with Inhibitors

Hybio Pharmaceutical’s Oral HY3003 Tablets Clear NMPA Clinical Trial Application Acceptance – A Class 1 GLP‑1R/GIPR/GCGR Triple Agonist for Weight Loss, Type 2 Diabetes, and MASH

Empowering Chinese Pharma’s Global Expansion

OBI Pharma Partners with TegMine to Develop Antibody-Drug Conjugates

EU Approves Pfizer and Takeda’s Adcetris in Hodgkin Lymphoma Combination Regimen

Biokin Pharma Enrolls First Patient in BL-M07D1 Phase III Trial for HER2 Low Breast Cancer

Alphamab Oncology Presents JSKN003 Clinical Data at 2025 ASCO Annual Meeting

Alphamab Oncology Presents JSKN003 Clinical Data at 2025 ASCO Annual Meeting

MSD Presents Zilovertamab Vedotin Results at ASCO Annual Meeting

CSPC Pharmaceutical in Advanced Talks for $5B Licensing Deals

Jiangsu Hengrui Secures NMPA Approvals for Trastuzumab Rezetecan, Famitinib and HR20013

About Company